Brent Hatzis-Schoch
2021 - Black Diamond Therapeutics
In 2021, Brent Hatzis-Schoch earned a total compensation of $2M as Chief Operating Officer, General Counsel at Black Diamond Therapeutics, a 32% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $149,226 |
|---|---|
| Option Awards | $1,411,832 |
| Salary | $438,901 |
| Other | $22,350 |
| Total | $2,022,309 |
Hatzis-Schoch received $1.4M in option awards, accounting for 70% of the total pay in 2021.
Hatzis-Schoch also received $149.2K in non-equity incentive plan, $438.9K in salary and $22.4K in other compensation.
Rankings
In 2021, Brent Hatzis-Schoch's compensation ranked 6,014th out of 12,415 executives tracked by ExecPay. In other words, Hatzis-Schoch earned more than 51.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,014 out of 12,415 | 52nd |
Division Manufacturing | 2,544 out of 5,501 | 54th |
Major group Chemicals And Allied Products | 1,111 out of 2,371 | 53rd |
Industry group Drugs | 989 out of 2,092 | 53rd |
Industry Biological Products, Except Diagnostic Substances | 242 out of 449 | 46th |
Source: SEC filing on April 28, 2022.
Hatzis-Schoch's colleagues
We found three more compensation records of executives who worked with Brent Hatzis-Schoch at Black Diamond Therapeutics in 2021.
News
Black Diamond Therapeutics CEO David Epstein's 2022 pay falls 68% to $1.6M
April 4, 2023
Black Diamond Therapeutics CEO David Epstein's 2021 pay jumps 32% to $5.1M
April 28, 2022
Radius Health CEO Jesper Hoeiland's 2019 pay falls 28% to $3.9M
April 17, 2020
Radius Health CEO Jesper Høiland's 2018 pay falls 29% to $5.4M
April 18, 2019